Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline–Update 2022
ML Gauci, C Aristei, JC Becker, A Blom… - European Journal of …, 2022 - Elsevier
Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all
cutaneous malignancies. It is found predominantly in white populations and risk factors …
cutaneous malignancies. It is found predominantly in white populations and risk factors …
[HTML][HTML] PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
BACKGROUND. PD-L1 expression and tumor mutational burden (TMB) have emerged as
important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These …
important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These …
Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial
PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …
Targeting neoantigens to augment antitumour immunity
The past decade of cancer research has been marked by a growing appreciation of the role
of immunity in cancer. Mutations in the tumour genome can cause tumours to express …
of immunity in cancer. Mutations in the tumour genome can cause tumours to express …
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy
PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …
Ferroptosis: a double-edged sword mediating immune tolerance of cancer
Q Dang, Z Sun, Y Wang, L Wang, Z Liu, X Han - Cell death & disease, 2022 - nature.com
The term ferroptosis was put forward in 2012 and has been researched exponentially over
the past few years. Ferroptosis is an unconventional pattern of iron-dependent programmed …
the past few years. Ferroptosis is an unconventional pattern of iron-dependent programmed …
PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
Background Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma …
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma …